mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
- Status
- UNKNOWN
- Phase
- NA
Clinical Trials Related to Irinotecan
Related studies linked through entity extraction aliases.
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
- Status
- UNKNOWN
- Phase
- PHASE2
Paediatric Hepatic International Tumour Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
- Status
- COMPLETED
- Phase
- PHASE3
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE3
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
- Status
- COMPLETED
- Phase
- PHASE3
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Nordic Pancreatic Cancer Trial (NorPACT) - 1
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
- Status
- RECRUITING
- Phase
- PHASE3
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Irinotecan as 3rd Line Therapy in Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1